Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.
2019
11Background: Pembrolizumab (PEM), an anti-PD-1 antibody, is approved for advanced urothelial cancer in the second-line setting (objective response rate [ORR] 21%) and in the first-line setting for...
Keywords:
- Correction
- Source
- Cite
- Save
0
References
6
Citations
NaN
KQI